+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Xadago

  • ID: 4775090
  • Report
  • June 2018
  • Region: Global
  • 15 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Xadago (safinamide; Newron Pharmaceuticals/US WorldMeds/Zambon/Meiji Seika Pharma) has a novel dual mechanism of action, based on the enhancement of the dopaminergic function through the reversible inhibition of monoamine oxidase B (MAO-B) and inhibition of excessive glutamate release by blocking the activity of the voltage-dependent sodium channels. Although Xadago was originally developed by Newron across the spectrum of Parkinson’s disease, it is approved only for mid-late stage Parkinson’s disease patients receiving levodopa and experiencing motor fluctuations. Its first approval came in the EU in February 2015, with a subsequent expansion to the US in March 2017.

Newron has sought out several commercial partners for Xadago, including out-licensing global rights to Zambon and Asian territory rights to Meiji Seika. Zambon has subsequently partnered with US WorldMeds for the drug’s commercialization in the US, while Eisai has obtained exclusive rights to Xadago in Japan.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Xadago : Parkinson's disease

LIST OF FIGURES
Figure 1: Xadago for Parkinson’s disease – SWOT analysis
Figure 2: The authors drug assessment summary of Xadago for Parkinson’s disease
Figure 3: The authors drug assessment summary of Xadago for Parkinson’s disease
Figure 4: Xadago sales for Parkinson’s disease across the US, Japan, and five major EU markets, by country, 2016–25

LIST OF TABLES
Table 1: Xadago drug profile
Table 2: Xadago pivotal trial data in Parkinson’s disease
Table 3: Xadago sales for Parkinson’s disease across the US, Japan, and five major EU markets, by country ($m), 2016–25
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll